GlassScriptPhysician profile
Yousef Abou Allaban
NPI 1922040666
$46,675.24
in general payments reported to CMS, 2019-2025
27 companies · $8,345 in 2025
The $8,345 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,072 · 2020: $565 · 2021: $1,484 · 2022: $1,604 · 2023: $17K · 2024: $16K · 2025: $8,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Food and Beverage: $5,882 · Travel and Lodging: $4,436 · Education: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,480.00 |
| Food and Beverage | $5,881.92 |
| Travel and Lodging | $4,435.76 |
| Education | $152.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $37,569.36 | 2019-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $2,164.69 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Mycite |
| Teva Pharmaceuticals USA, INC. | $1,241.28 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $947.86 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $596.81 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $592.23 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $568.21 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $563.24 | 2021-2025 | Vraylar |
| Lundbeck LLC | $541.01 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $271.87 | 2019-2023 | Trintellix |
| Axsome Therapeutics, INC. | $265.96 | 2023-2025 | Auvelity, Sunosi |
| Sunovion Pharmaceuticals INC. | $245.05 | 2019-2020 | |
| Allergan, INC. | $244.84 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $169.09 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $128.28 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $118.04 | 2022-2023 | Azstarys |
| Tempus Ai, INC | $87.21 | 2024 | |
| Livanova USA, INC. | $53.61 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Acadia Pharmaceuticals INC | $52.78 | 2023 | Daybue |
| Shire North American Group INC | $47.94 | 2019 | |
| Idorsia Pharmaceuticals US INC | $46.88 | 2022-2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $44.44 | 2023-2024 | Qelbree, Qelbree |
| Almatica Pharma LLC | $32.96 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $26.48 | 2025 | Rejoyn |
| Bausch Health US, LLC | $25.43 | 2022 | |
| Collegium Pharmaceutical, INC. | $15.78 | 2025 | Jornay Pm |
| Eisai INC. | $13.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yousef Abou Allaban listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.